Nov. 19, 2025 -- RespireRx Pharmaceuticals Inc. (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce the receipt of a Notice of Award of a grant from the NIH/NINDS and entry into an Amended and Restated Patent License Agreement with the University of Wisconsin Research Foundation. On September 23, 2025, RespireRx received a Notice of Award from t

The Company has a global license agreement for the acute pulmonary that could pay up to $78.9 million in development, regulatory and commercial milestones plus low double digit royalties The licensed treatments include SURFAXIN®, lyophilized lucinactant and AEROSURF® (a drug and device combination) The franchise is intended to treat premature infants with respiratory distress syndrome (RDS) Windtree will communicate more information about milestone payments it may receive from its licensing part

Nov. 17, 2025 -- Angiex Inc., a developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, today announced the completion of financings totaling $31 million, with participation from new and existing investors. The proceeds are being used to advance AGX101, a first-in-class TM4SF1-directed ND-ADC, through the dose-escalation portion of the Phase 1 clinical trial, which is designed to assess safety, tolerability and preliminary clinical activity. “Angiex is ver

Nov. 14, 2025 -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, announces the closing of the first tranche (the “First Tranche”) of its non-brokered private placement (the “Offering”), previously announced on November 6, 2025. Gross proceeds from the First Tranche totaled CAD $177,000 from the sale of 2,528,752 units (the “Units”) at an issue price of CAD $0.07 per Unit. Certain insiders of the Company participated

$32 million new equity injection adds to previously announced $59 million New investors Tencent and BGF joined by all existing major shareholders Funds will advance pipeline of novel TCR-CD3 bispecifics in cancer and autoimmune disease 13 November 2025 – T-Therapeutics, a biotechnology company developing next-generation T cell receptor (TCR) therapeutics for cancer and autoimmune disease, today announces the successful expansion of its Series A financing, raising a further $32 million. Followi

New funding brings total capital raised to $135 million Molecular gates offer the convenience of a pill with potential for superior efficacy through a novel mechanism that eliminates disease-causing proteins at their source Financing will support clinical development of differentiated small molecule therapies targeting high-value inflammatory and neurological disease proteins Nov. 13, 2025 -- Gate Bioscience, a biotechnology company developing a new class of small molecule medicines aiming to

Preclinical research to be conducted at the University of North Carolina at Chapel Hill (UNC) Annamycin will be used in conjunction with novel agents and modalities Preclinical studies indicate Annamycin targets key factors in pancreatic cancer Nov. 12, 2025 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced it has entered i

Nov. 10, 2025 -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing new treatments for patients suffering from recurrent and metastatic cancer, today announced that it has entered into a securities purchase agreement with Hexstone Capital LLC ("Hexstone"), a family office that has invested in a significant number of Digital Asset Treasury (DAT) companies across a range of digital assets including BTC, ETH, SOL, DOGE, ATH, OG, and INJ. The

Nov. 06, 2025 -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, announced today that it secures non-dilutive investment for its subsidiary, LongevityBank Pte Ltd (“LongevityBank”) from ICH Capital Pte Ltd (“ICH

First company to enable precision in vivo genome engineering, combining both cell-specific delivery and programmable, locus-specific gene insertion, with the potential to achieve physiological, durable gene expression for greater therapeutic impact Launching with $82 million in combined seed and Series A financing led by Third Rock Ventures, with participation from RA Capital Management, Yosemite, Sozo Ventures and select individual investors Founded by Jennifer Doudna, Ph.D., Michael Fischbach,